89BIO INC(NASDAQ:ETNB) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to ETNB. ETNB was compared to 566 industry peers in the Biotechnology industry. ETNB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ETNB is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ETNB has reported negative net income.

ETNB had a negative operating cash flow in the past year.

ETNB had negative earnings in each of the past 5 years.

ETNB had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -76.68%, ETNB is doing worse than 68.20% of the companies in the same industry.

The Return On Equity of ETNB (-91.59%) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-76.68%
ROE	-91.59%
ROIC	N/A

ROA(3y)-50.79%

ROA(5y)-46.26%

ROE(3y)-61.77%

ROE(5y)-56.24%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ETNB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ETNB has more shares outstanding than it did 1 year ago.

The number of shares outstanding for ETNB has been increased compared to 5 years ago.

The debt/assets ratio for ETNB is higher compared to a year ago.

2.2 Solvency

ETNB has an Altman-Z score of 5.18. This indicates that ETNB is financially healthy and has little risk of bankruptcy at the moment.

Looking at the Altman-Z score, with a value of 5.18, ETNB belongs to the top of the industry, outperforming 81.27% of the companies in the same industry.

A Debt/Equity ratio of 0.09 indicates that ETNB is not too dependend on debt financing.

ETNB's Debt to Equity ratio of 0.09 is on the low side compared to the rest of the industry. ETNB is outperformed by 64.66% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.09
Debt/FCF	N/A
Altman-Z	5.18

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

ETNB has a Current Ratio of 13.19. This indicates that ETNB is financially healthy and has no problem in meeting its short term obligations.

The Current ratio of ETNB (13.19) is better than 86.93% of its industry peers.

ETNB has a Quick Ratio of 13.19. This indicates that ETNB is financially healthy and has no problem in meeting its short term obligations.

ETNB's Quick ratio of 13.19 is amongst the best of the industry. ETNB outperforms 86.93% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	13.19
Quick Ratio	13.19

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for ETNB have decreased strongly by -70.65% in the last year.

EPS 1Y (TTM)-70.65%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-104%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 13.91% on average over the next years. This is quite good.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y39.47%

EPS Next 2Y17.7%

EPS Next 3Y12.74%

EPS Next 5Y13.91%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ETNB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ETNB. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ETNB's earnings are expected to grow with 12.74% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y17.7%

EPS Next 3Y12.74%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ETNB does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

89BIO INC

NASDAQ:ETNB (5/1/2025, 8:58:04 PM)

Premarket: 7.8 -0.33 (-4.06%)

8.13

+0.11 (+1.37%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)02-27 2025-02-27/amc

Earnings (Next)05-07 2025-05-07/amc

Inst Owners100.95%

Inst Owner Change0.24%

Ins Owners1.33%

Ins Owner Change18.27%

Market Cap1.19B

Analysts84.71

Price Target28.1 (245.63%)

Short Float %11.89%

Short Ratio8.9

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)0

Avg EPS beat(2)-71.04%

Min EPS beat(2)-112.45%

Max EPS beat(2)-29.63%

EPS beat(4)1

Avg EPS beat(4)-34.86%

Min EPS beat(4)-112.45%

Max EPS beat(4)17.4%

EPS beat(8)3

Avg EPS beat(8)-18.39%

EPS beat(12)6

Avg EPS beat(12)-7.99%

EPS beat(16)7

Avg EPS beat(16)-9.33%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-7.15%

PT rev (3m)-9.05%

EPS NQ rev (1m)-1.6%

EPS NQ rev (3m)27.91%

EPS NY rev (1m)-4.22%

EPS NY rev (3m)31.29%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	2.96
P/tB	2.96
EV/EBITDA	N/A

EPS(TTM)-3.43

EYN/A

EPS(NY)-2.08

Fwd EYN/A

FCF(TTM)-2.52

FCFYN/A

OCF(TTM)-2.52

OCFYN/A

SpS0

BVpS2.75

TBVpS2.75

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-76.68%
ROE	-91.59%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-50.79%

ROA(5y)-46.26%

ROE(3y)-61.77%

ROE(5y)-56.24%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score2

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.09
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	39.47%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	13.19
Quick Ratio	13.19
Altman-Z	5.18

F-Score2

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)20.59%

Cap/Depr(5y)70.69%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-70.65%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-104%

EPS Next Y39.47%

EPS Next 2Y17.7%

EPS Next 3Y12.74%

EPS Next 5Y13.91%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-154.39%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year7.71%

EBIT Next 3Y-4.05%

EBIT Next 5YN/A

FCF growth 1Y-184.73%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-184.72%

OCF growth 3YN/A

OCF growth 5YN/A

89BIO INC (ETNB) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens